Charlotte Feehan ‘24

I am studying monoclonal antibody therapies and their potential to be effective treatments for breast cancer. Monoclonal antibodies are lab-engineered molecules with the ability to identify and attack tumor-specific antigens. In recent years they have become the most promising passive immunotherapy in the medical field. Currently, I am researching monoclonal antibody drugs that are designed for patients of aggressive breast cancers, as well as the effect that they will have in future treatment.

Why did you pursue this project?
Hi, I’m Charlotte! Through the ISRP, I have been able to refine and develop my research skills, as well as explore my interests in the medical field. Outside of school, I play three varsity sports, all of which have taught me the importance of teamwork, collaboration, and communication on and off the field. I spend my free time reading novels as well as medical journals and research papers to stay updated on current events and recent discoveries in various fields.

I find it inspiring that science offers a logical approach to solving problems in the world. In particular, I have always felt that I wanted to utilize my passion for the medical field to help discover life-changing treatments for diseases that affect millions of people globally. In my free time I enjoy reading medical journals and papers, so when I came across an article detailing a monoclonal antibody combination designed to treat COVID-19, I wanted to know more.  The idea that these therapies could weaponize a person’s immune system to combat such a debilitating and devastating disease is fascinating to me, and through my combined interests in oncology and immunology, I have greatly enjoyed studying monoclonal antibodies in HER2+ breast cancer for this past year.